Twist Bioscience Corporation $TWST Shares Acquired by EdgePoint Investment Group Inc.

EdgePoint Investment Group Inc. lifted its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 71.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,082,319 shares of the company’s stock after acquiring an additional 1,696,377 shares during the quarter. Twist Bioscience accounts for approximately 0.9% of EdgePoint Investment Group Inc.’s investment portfolio, making the stock its 22nd biggest holding. EdgePoint Investment Group Inc. owned approximately 6.76% of Twist Bioscience worth $114,876,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Smartleaf Asset Management LLC raised its holdings in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the period. Geneos Wealth Management Inc. acquired a new stake in Twist Bioscience in the second quarter valued at approximately $97,000. CWM LLC increased its position in shares of Twist Bioscience by 61.4% in the third quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after buying an additional 1,648 shares in the last quarter. AXQ Capital LP purchased a new stake in shares of Twist Bioscience in the second quarter valued at approximately $226,000. Finally, Bayesian Capital Management LP acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $253,000.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of research analyst reports. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Barclays lifted their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Finally, Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.88.

Twist Bioscience Trading Up 0.6%

Shares of TWST stock opened at $43.28 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock’s fifty day moving average is $44.94 and its two-hundred day moving average is $35.22. The firm has a market capitalization of $2.65 billion, a P/E ratio of -33.81 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm’s revenue for the quarter was up 16.9% compared to the same quarter last year. Research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 935 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $46.43, for a total transaction of $43,412.05. Following the transaction, the senior vice president directly owned 124,401 shares in the company, valued at $5,775,938.43. The trade was a 0.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jan Johannessen sold 2,200 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $47.91, for a total value of $105,402.00. Following the completion of the sale, the director owned 17,754 shares of the company’s stock, valued at $850,594.14. This trade represents a 11.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 40,392 shares of company stock worth $1,840,796 in the last 90 days. 3.08% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.